Cargando…

Dedifferentiated endometrioid adenocarcinoma with trophoblastic components: Prolonged remission after treatment with bleomycin, etoposide, and cisplatin

Dedifferentiated endometrial adenocarcinoma (DEAC) with trophoblastic components is a rare neoplasm with an aggressive behavior and a poor prognosis. Only seven cases have been reported in the literature. We present a 61-year-old patient who was diagnosed with Stage IB dedifferentiated endometrioid...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Alexa K., Jackson, Elizabeth G., Edwards, Henry D., Stany, Michael P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103773/
https://www.ncbi.nlm.nih.gov/pubmed/32258333
http://dx.doi.org/10.1016/j.gore.2020.100562
_version_ 1783512109481459712
author Martin, Alexa K.
Jackson, Elizabeth G.
Edwards, Henry D.
Stany, Michael P.
author_facet Martin, Alexa K.
Jackson, Elizabeth G.
Edwards, Henry D.
Stany, Michael P.
author_sort Martin, Alexa K.
collection PubMed
description Dedifferentiated endometrial adenocarcinoma (DEAC) with trophoblastic components is a rare neoplasm with an aggressive behavior and a poor prognosis. Only seven cases have been reported in the literature. We present a 61-year-old patient who was diagnosed with Stage IB dedifferentiated endometrioid adenocarcinoma with trophoblastic elements. A post-operative β-hCG was elevated at 1877 mIU/mL. The patient received 6 cycles of carboplatin and paclitaxel with normalization of β-hCG; however, three months after completion of chemotherapy, her β-hCG increased to 39 mIU/mL and a mass overlaying the psoas muscle was noted on imaging. The mass was resected and confirmed to be recurrent disease. Four cycles of bleomycin, etoposide, and cisplatin were administered, and the patient remains without evidence of disease 3 years after completing treatment. Due to the small number of reported cases of DEAC with trophoblastic components, there is limited information regarding the appropriate first-line adjuvant chemotherapy regimen.
format Online
Article
Text
id pubmed-7103773
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-71037732020-03-31 Dedifferentiated endometrioid adenocarcinoma with trophoblastic components: Prolonged remission after treatment with bleomycin, etoposide, and cisplatin Martin, Alexa K. Jackson, Elizabeth G. Edwards, Henry D. Stany, Michael P. Gynecol Oncol Rep Case Report Dedifferentiated endometrial adenocarcinoma (DEAC) with trophoblastic components is a rare neoplasm with an aggressive behavior and a poor prognosis. Only seven cases have been reported in the literature. We present a 61-year-old patient who was diagnosed with Stage IB dedifferentiated endometrioid adenocarcinoma with trophoblastic elements. A post-operative β-hCG was elevated at 1877 mIU/mL. The patient received 6 cycles of carboplatin and paclitaxel with normalization of β-hCG; however, three months after completion of chemotherapy, her β-hCG increased to 39 mIU/mL and a mass overlaying the psoas muscle was noted on imaging. The mass was resected and confirmed to be recurrent disease. Four cycles of bleomycin, etoposide, and cisplatin were administered, and the patient remains without evidence of disease 3 years after completing treatment. Due to the small number of reported cases of DEAC with trophoblastic components, there is limited information regarding the appropriate first-line adjuvant chemotherapy regimen. Elsevier 2020-03-18 /pmc/articles/PMC7103773/ /pubmed/32258333 http://dx.doi.org/10.1016/j.gore.2020.100562 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Martin, Alexa K.
Jackson, Elizabeth G.
Edwards, Henry D.
Stany, Michael P.
Dedifferentiated endometrioid adenocarcinoma with trophoblastic components: Prolonged remission after treatment with bleomycin, etoposide, and cisplatin
title Dedifferentiated endometrioid adenocarcinoma with trophoblastic components: Prolonged remission after treatment with bleomycin, etoposide, and cisplatin
title_full Dedifferentiated endometrioid adenocarcinoma with trophoblastic components: Prolonged remission after treatment with bleomycin, etoposide, and cisplatin
title_fullStr Dedifferentiated endometrioid adenocarcinoma with trophoblastic components: Prolonged remission after treatment with bleomycin, etoposide, and cisplatin
title_full_unstemmed Dedifferentiated endometrioid adenocarcinoma with trophoblastic components: Prolonged remission after treatment with bleomycin, etoposide, and cisplatin
title_short Dedifferentiated endometrioid adenocarcinoma with trophoblastic components: Prolonged remission after treatment with bleomycin, etoposide, and cisplatin
title_sort dedifferentiated endometrioid adenocarcinoma with trophoblastic components: prolonged remission after treatment with bleomycin, etoposide, and cisplatin
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103773/
https://www.ncbi.nlm.nih.gov/pubmed/32258333
http://dx.doi.org/10.1016/j.gore.2020.100562
work_keys_str_mv AT martinalexak dedifferentiatedendometrioidadenocarcinomawithtrophoblasticcomponentsprolongedremissionaftertreatmentwithbleomycinetoposideandcisplatin
AT jacksonelizabethg dedifferentiatedendometrioidadenocarcinomawithtrophoblasticcomponentsprolongedremissionaftertreatmentwithbleomycinetoposideandcisplatin
AT edwardshenryd dedifferentiatedendometrioidadenocarcinomawithtrophoblasticcomponentsprolongedremissionaftertreatmentwithbleomycinetoposideandcisplatin
AT stanymichaelp dedifferentiatedendometrioidadenocarcinomawithtrophoblasticcomponentsprolongedremissionaftertreatmentwithbleomycinetoposideandcisplatin